From the Guidelines
The ICD-10 code for hyperuricemia, which is relevant to uric acid levels of 9.3, is E79.0. This code is specifically used for conditions related to elevated uric acid levels in the blood, including gout and other disorders of purine metabolism 1. When considering the management of gout, it's essential to note that initiating urate-lowering therapy (ULT) is strongly recommended for patients with certain conditions, such as subcutaneous tophi, radiographic damage, or frequent gout flares, as indicated by the 2020 American College of Rheumatology guideline for the management of gout 1. Some key points to consider in the management of gout include:
- Initiating ULT is strongly recommended for gout patients with any of the following: ≥1 subcutaneous tophi; evidence of radiographic damage (any modality) attributable to gout; OR frequent gout flares, with frequent being defined as ≥2 annually 1.
- For patients with less frequent flares and no tophi, the potential clinical benefit of ULT would be lower than the ULT benefit for patients with more burdensome gout 1.
- Specific characteristics for patients with infrequent flares (e.g., SU concentration >9 mg/dl, CKD, CVD) that might influence the risk‑benefit assessment were considered, but due to insufficient data for these subgroups, the Voting Panel did not find that these conditions warranted stronger ULT recommendations specific to these subgroups 1. However, for patients with uric acid levels of 9.3, the primary concern is managing the underlying condition causing the elevated uric acid levels, and the ICD-10 code E79.0 is the most relevant code for hyperuricemia.
From the Research
Utica Acid 9.3 ICD Code
There are no research papers to assist in answering this question about the Utica acid 9.3 ICD code. The provided studies focus on various aspects of uric acid, hyperuricemia, and related treatments, but none of them mention the Utica acid 9.3 ICD code specifically.
Relevant Information on Uric Acid
- Uric acid is a waste product that can cause kidney stones and gouty-type arthritis when present in high concentrations 2.
- Hyperuricemia is a health hazard with a high incidence in certain populations, and its risk factors include gender, hypertension, use of diuretics, frequency of meat consumption, sedentary lifestyle, and BMI 3.
- Urate-lowering therapy includes xanthine oxidase inhibitors that reduce uric acid production, as well as uricosuric drugs that increase urea excretion 4, 5.
- The role of uric acid in health and disease is complex, with both physiological and pathological functions, and its levels are strictly maintained by multiple enzymes and transporters 6.
Key Findings on Uric Acid Treatment
- Xanthine oxidase inhibitors, such as allopurinol and febuxostat, are effective and safe for chronic treatment of hyperuricemia 4.
- Febuxostat may be more effective than allopurinol in reducing the risk of progression to dialysis and in lowering serum uric acid levels in chronic kidney disease populations 5.
- Natural products, such as phenolics and triterpenes, have potential as new xanthine oxidase inhibitors for the treatment of gout disease 2.